Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Relapsing Remitting Multiple Sclerosis Pipeline Insight

DelveInsight’s, “Relapsing-Remitting Multiple Sclerosis - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Relapsing-Remitting Multiple Sclerosis Understanding

Relapsing-Remitting Multiple Sclerosis: Overview

Relapsing-Remitting Multiple Sclerosis (RRMS) - the most common disease course – is characterized by clearly defined attacks of new or increasing neurologic symptoms. These attacks – also called relapses or exacerbations – are followed by periods of partial or complete recovery (remissions). During remissions, all symptoms may disappear, or some symptoms may continue and become permanent. However, there is no apparent progression of the disease during the periods of remission.RRMS can be further characterized as either active (with relapses and/or evidence of new MRI activity over a specified period of time) or not active, as well as worsening (a confirmed increase in disability following a relapse) or not worsening. Approximately 85 percent of people with MS are initially diagnosed with RRMS.


"Relapsing-Remitting Multiple Sclerosis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Relapsing-Remitting Multiple Sclerosis pipeline landscape is provided which includes the disease overview and Relapsing-Remitting Multiple Sclerosis treatment guidelines. The assessment part of the report embraces, in depth Relapsing-Remitting Multiple Sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsing-Remitting Multiple Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Relapsing-Remitting Multiple Sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Relapsing-Remitting Multiple Sclerosis.

Relapsing-Remitting Multiple Sclerosis Emerging Drugs Chapters

This segment of the Relapsing-Remitting Multiple Sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Relapsing-Remitting Multiple Sclerosis Emerging Drugs


Orelabrutinib: InnoCare Pharma

Orelabrutinib is an orally bioavailable small molecule Bruton's tyrosine kinase-inhibitor (agammaglobulinaemia tyrosine kinase inhibitor), developed by InnoCare Pharma. The drug is in phase 2 stage of development for the treatment of Relapsing Remitting Multiple Sclerosis.


BCD-063: Biocad

Biocad is developing glatiramer acetate, designated BCD 063, for the treatment of Relapsing-Remitting Multiple Sclerosis. It is a MHC class II gene modulators and is currently in phase 3 stage of development.


Evobrutinib: Merck

Evobrutinib (M2951) is in clinical development to investigate its potential as a treatment for multiple sclerosis (MS). It is an oral, highly selective inhibitor of Bruton’s tyrosine kinase (BTK) which is important in the development and functioning of various immune cells including B lymphocytes and macrophages. Evobrutinib is designed to inhibit primary B cell responses such as proliferation and antibody and cytokine release, without directly affecting T cells. BTK inhibition is thought to suppress autoantibody-producing cells, which preclinical research suggests may be therapeutically useful in certain autoimmune diseases. Evobrutinib is currently under clinical investigation and not approved for any use anywhere in the world.

Further product details are provided in the report……..

Relapsing-Remitting Multiple Sclerosis: Therapeutic Assessment

This segment of the report provides insights about the different Relapsing-Remitting Multiple Sclerosis drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Relapsing-Remitting Multiple Sclerosis

There are approx. 25+ key companies which are developing the therapies for Relapsing-Remitting Multiple Sclerosis. The companies which have their Relapsing-Remitting Multiple Sclerosis drug candidates in the most advanced stage, i.e. phase III include, Biocad.

Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Relapsing-Remitting Multiple Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Relapsing-Remitting Multiple Sclerosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsing-Remitting Multiple Sclerosis therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsing-Remitting Multiple Sclerosis drugs.

Relapsing-Remitting Multiple Sclerosis Report Insights

  • Relapsing-Remitting Multiple Sclerosis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Relapsing-Remitting Multiple Sclerosis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Relapsing-Remitting Multiple Sclerosis drugs?
  • How many Relapsing-Remitting Multiple Sclerosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Relapsing-Remitting Multiple Sclerosis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Relapsing-Remitting Multiple Sclerosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Relapsing-Remitting Multiple Sclerosis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Relapsing-Remitting Multiple Sclerosis: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Relapsing-Remitting Multiple Sclerosis – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Relapsing-Remitting Multiple Sclerosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Relapsing-Remitting Multiple Sclerosis Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Evobrutinib: Merck

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

RHB-104: RedHill Biopharma Limited

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Relapsing-Remitting Multiple Sclerosis Key Companies

Relapsing-Remitting Multiple Sclerosis Key Products

Relapsing-Remitting Multiple Sclerosis- Unmet Needs

Relapsing-Remitting Multiple Sclerosis- Market Drivers and Barriers

Relapsing-Remitting Multiple Sclerosis- Future Perspectives and Conclusion

Relapsing-Remitting Multiple Sclerosis Analyst Views

Relapsing-Remitting Multiple Sclerosis Key Companies

Appendix

List of Table

Table 1: Total Products for Relapsing-Remitting Multiple Sclerosis

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Relapsing-Remitting Multiple Sclerosis

Figure 2: Late Stage Products                               

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• InnoCare Pharma

• Biocad

• Biogen

• RedHill Biopharma Limited

• Immunic AG

• Merck Serono

• Anokion SA

• Apitope Technology

• Neurotec Pharma

• Mitsubishi Tanabe Pharma Corporation

• TG Therapeutics, Inc.

• RemeGen Co., Ltd.

• Gilead Sciences

• GlaxoSmithKline

• GeNeuro SA

• InteKrin Therapeutics, Inc.

• Clene Nanomedicine

• Takeda Pharmaceuticals

• Mapi Pharma Ltd.

Forward to Friend

Need A Quote